Sinco Pharmaceuticals Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sinco Pharmaceuticals Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth	19.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Apr 02

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Mar 08

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Nov 07

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Jun 26

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

May 30

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

Oct 26

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Feb 04

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

Oct 25

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Jun 10

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

May 24

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Apr 20

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Feb 16

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 11

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Dec 07

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinco Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:6833 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	2,540	42	306	354	N/A
9/30/2023	2,386	35	331	383	N/A
6/30/2023	2,232	27	355	413	N/A
3/31/2023	2,252	48	189	244	N/A
12/31/2022	2,272	69	22	75	N/A
9/30/2022	2,289	96	145	193	N/A
6/30/2022	2,307	122	268	312	N/A
3/31/2022	2,165	128	275	309	N/A
12/31/2021	2,024	135	282	306	N/A
9/30/2021	2,142	148	294	307	N/A
6/30/2021	2,261	161	305	308	N/A
3/31/2021	2,155	140	221	222	N/A
12/31/2020	2,050	118	137	137	N/A
9/30/2020	1,664	79	-40	-40	N/A
6/30/2020	1,277	41	-218	-217	N/A
3/31/2020	1,227	32	-114	-113	N/A
12/31/2019	1,176	24	-10	-10	N/A
9/30/2019	1,045	-97	135	136	N/A
6/30/2019	915	-217	281	281	N/A
3/31/2019	934	-249	268	269	N/A
12/31/2018	953	-281	255	256	N/A
9/30/2018	960	-242	38	40	N/A
6/30/2018	966	-203	-179	-177	N/A
3/31/2018	886	-195	-271	-268	N/A
12/31/2017	807	-186	-363	-359	N/A
9/30/2017	755	-115	N/A	-243	N/A
6/30/2017	704	-43	N/A	-127	N/A
3/31/2017	781	-12	N/A	-78	N/A
12/31/2016	859	19	N/A	-30	N/A
9/30/2016	958	36	N/A	-6	N/A
6/30/2016	1,057	52	N/A	17	N/A
3/31/2016	1,076	61	N/A	32	N/A
12/31/2015	1,096	70	N/A	46	N/A
9/30/2015	1,120	77	N/A	87	N/A
6/30/2015	1,144	84	N/A	128	N/A
3/31/2015	1,047	77	N/A	91	N/A
12/31/2014	950	69	N/A	53	N/A
12/31/2013	532	37	N/A	78	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6833's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 6833's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 6833's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 6833's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 6833's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6833's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Sinco Pharmaceuticals Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings

Dividend reduced to HK$0.0039

Sinco Pharmaceuticals Holdings Limited Proposes Final Cash Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

Sinco Pharmaceuticals Holdings Limited Resignation of Li Kin Wai as Joint Company Secretary and Appointment of Peng Yunlu as Executive Director

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 20% overvalued

Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks

Now 20% overvalued

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

New minor risk - Share price stability

First half 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.03 in 1H 2022)

Now 20% undervalued after recent price drop

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2023 Results on Aug 30, 2023

A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)

Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?

Full year 2022 earnings released: EPS: CN¥0.034 (vs CN¥0.078 in FY 2021)

Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet

First half 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.044 in 1H 2021)

Sinco Pharmaceuticals Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: CN¥0.078 (vs CN¥0.07 in FY 2020)

Sinco Pharmaceuticals Holdings Limited, Annual General Meeting, May 13, 2022

Investor sentiment improved over the past week

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today

Sinco Pharmaceuticals Holdings Limited (SEHK:6833) entered into a letter of interest to acquire Deyang Demei Medical Aesthetic Clinic from Jiang Biao, Jiang Min and Jiang Jun.

Investor sentiment deteriorated over the past week

Sinco Pharmaceuticals Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 206.4 million.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.019 in 1H 2020)

Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings

Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock

Joint Company Secretary has left the company

Full year 2020 earnings released: EPS CN¥0.07 (vs CN¥0.014 in FY 2019)

Sinco Pharmaceuticals Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$0.32

We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings

Sinco Pharmaceuticals Holdings Limited Announces Management Changes

How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?

Sinco Pharmaceuticals Holdings Limited Announces Board Changes

New 90-day low: HK$0.26

Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?

Sinco Pharmaceuticals Holdings Limited Appoints Jin Min as Co-Chief Executive Officer

New 90-day high - HK$0.30

Sinco Pharmaceuticals Holdings Limited to Report Q2, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies